Another Major Drug Approval for Regeneron
Congratulations to BCW member Regeneron on the approval of an important new drug to help patients with rheumatoid arthritis. The U.S. Food and Drug Administration has approved the human antibody drug sarilumab, developed by Regeneron Pharmaceuticals Inc. in Westchester and its French pharmaceutical partner Sanofi and trademarked as Kevzara, to treat adult patients with moderately to severely active rheumatoid arthritis.
The FDA approval came less than two months after the federal agency approved Regeneron’s and Sanofi’s human antibody dupilumab, marketed as Dupixent, as the first biologic medicine used to treat the debilitating itching and widespread rashes afflicting adults with moderate to severe cases of atopic dermatitis.
Similar News Items
BCW Member Iona University proudly celebrated its newly renovated dining hall and student union with a ribbon cutting ceremony held Wednesday, marking a major milestone in its ongoing commitment to elevating the student experience. The 20,000-square-foot, two-story transformation of the LaPenta Student Union reflects a vibrant vision of campus life, one that fosters connection, curiosity […]
Congratulations to BCW Member Lightbridge Academy child-care center franchise that recently celebrated the grand opening of its newest location at 26 Legion Drive in Valhalla. The center is the newest of the more than 160 that the company operates or are in development. The franchisees are Vivian and Mark Mathias, who already own a Scarsdale […]
BCW Member Pace University announced this week the appointment of Ajay Khorana, Ph.D., as Dean of the Lubin School of Business and professor of finance, effective September 1, 2025. Pace President Marvin Krislov praised Khorana’s impressive background in global finance, commitment to student and institutional success, and ability to bridge industry and academia. “Ajay Khorana is a […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.